Bull&Bear | Newsmax Skyrockets 2230% as Investors Flock to Bull Stocks

In the realm of bull stocks, Newsmax (NMAX) experienced a remarkable increase of 179.01%. Over the course of just two days since its listing, the American conservative media company has surged by an impressive 2230%, leading its market capitalization to surpass that of Fox. This extraordinary growth highlights the substantial investor interest and speculative activity surrounding Newsmax.

Marblegate (GATE) saw an 83.83% increase. On March 31st, Marblegate Acquisition Corp. reported a trading volume reaching $795,800, indicating sustained market interest and active trading of its shares. This is a significant sign that investors continue to see potential value in the company, fueling its upward trajectory.

SatixFy (SATX) demonstrated a 64.17% rise following the release of its full-year fiscal 2024 earnings report. The communications company announced revenues of $20.6 million, showcasing a year-over-year increase from $10.7 million. This growth underscores the company's successful operations and ability to expand its market presence.

Quantum Song (QSG) increased by 63.68% and has seen continuous gains for six days, amounting to a 143.70% rise over the past six-day period. The company's successful acquisition of Letsvan demonstrates its commitment to deeper involvement in the trendy entertainment industry, driving investor confidence.

Nutex Health (NUTX) rose by 51.82%. The firm received a reaffirmed 'buy' rating with a target price of $60, reflecting favorable analyst sentiment and expectations for further growth. These positive endorsements have likely contributed to its stock price surge.

In the realm of bear stocks, Open Lending (LPRO) plummeted by 57.61%, marking a continuous six-day decline totaling a 64.55% drop over the recent period. The company reported a GAAP earnings per share (EPS) for the fourth quarter of $(1.21), significantly missing expectations of $0.02, alongside sales figures of $(56.92M), which were below the anticipated $23.65M. These disappointing results have severely impacted investor confidence.

Corcept Therapeutics (CORT) suffered a 19.51% decline, down over 14% in a swift drop that may mark its biggest percentage fall since January 2024. The downturn signifies waning investor sentiment and possible challenges faced by the firm.

Phathom (PHAT) experienced an 18.34% decrease, entering a three-day consecutive decline, culminating in a 23.47% drop over the three-day span. The announcement of Stephen Basta as the new CEO, succeeding Terry Kalan who resigned for personal reasons, might have contributed to investor uncertainty regarding leadership changes.

Neurogene (NGNE) fell by 17.55%, marking four consecutive days of downturn, with a total decrease of 40.18% over the past four days. Despite revealing 2024 financial results and progress in Rett syndrome clinical trials, the news hasn’t favored the stock, potentially due to uncertainty regarding clinical trial outcomes or future prospects.

Gyre Therapeutics (GYRE) saw a 16.97% drop, continuing its decline for two days, resulting in a total 29.64% decrease over this period. The company's announcement of receiving NMPA approval to conduct clinical trials assessing pirfenidone capsules for lung complications related to tumors might have negatively impacted stock prices. Clinical trials inherently carry risks of failure, increasing investor anxiety about the company's future outlook.